ReviewAntioxidants & redox signaling2019
Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases.
Review in Antioxidants & redox signaling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Ubiquitination in intervertebral disc degeneration: from mechanisms to potential therapeutic strategies.Journal of orthopaedic translation · 2026Review
- Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities.Exploration of targeted anti-tumor therapy · 2026Review
- Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-κB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Reactive oxygen species in hypertension.Nature reviews. Cardiology · 2025Review
- Oxidative Stress in Cardiovascular Diseases: Mechanisms and Exploring Advanced Therapies.Cardiovascular & hematological agents in medicinal chemistry · 2025Review
- An Explicative Review on Nanotechnology-based Drug Delivery Systems for Alleviating Oxidative Stress-driven Pathologies.Current drug metabolism · 2025Review
- The Role of Antioxidants in the Therapy of Cardiovascular Diseases-A Literature Review.Nutrients · 2024Review
- Advances in Atherosclerosis Theranostics Harnessing Iron Oxide-Based Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Rosmarinic Acid-RichMolecules (Basel, Switzerland) · 2024Article
- Immune cell-mediated features of atherosclerosis.Frontiers in cardiovascular medicine · 2024Review
- Near Infrared Light-Activatable Platelet-Mimicking NIR-II NO Nano-Prodrug for Precise Atherosclerosis Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Immunomodulation in age-related disorders and nanotechnology interventions.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- ROS-Based Nanoparticles for Atherosclerosis Treatment.Materials (Basel, Switzerland) · 2021Review
- Recent Advances in ROS-Sensitive Nano-Formulations for Atherosclerosis Applications.Pharmaceutics · 2021Review
- ROS-responsive biomimetic nanoparticles for potential application in targeted anti-atherosclerosis.Regenerative biomaterials · 2021Article
- Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis.Acta pharmacologica Sinica · 2021Review
- The Role of Nanomaterials in Stroke Treatment: Targeting Oxidative Stress.Oxidative medicine and cellular longevity · 2021Review
- Oxidative Stress and Antioxidant Treatments in Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2020Review
- Biomimetic fibrin-targeted and HNano today · 2020Article
- Systemic Review of Biodegradable Nanomaterials in Nanomedicine.Nanomaterials (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
significanceNanomedicine is an application of nanotechnology that provides solutions to unmet medical challenges. The unique features of nanoparticles, such as their small size, modifiable components, and diverse functionality, make them attractive and suitable materials for novel diagnostic, therapeutic, or theranostic applications. Cardiovascular diseases (CVDs) are the major cause of noncommunicable illness in both developing and developed countries. Nanomedicine offers novel theranostic options for the treatment of CVDs. Recent Advances: Many innovative nanoparticles to target reactive oxygen species (ROS) have been developed. In this article, we review the characteristics of nanoparticles that are responsive to ROS, their limitations, and their potential clinical uses. Significant advances made in diagnosis of atherosclerosis and treatment of acute coronary syndrome using nanoparticles are discussed. CRITICAL ISSUES: Although there is a tremendous potential for the nanoparticle applications in medicine, their safety should be considered while using in humans. We discuss the challenges that may be encountered with some of the innovative nanoparticles used in CVDs. FUTURE DIRECTIONS: The unique properties of nanoparticles offer novel diagnostic tool and potential therapeutic strategies. However, nanomedicine is still in its infancy, and further in-depth studies are needed before wide clinical application is achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.